Milestone Pharmaceuticals Inc.

Milestone Pharmaceuticals Inc. Earnings Recaps

MIST Financials 3 recaps
Next earnings: March 19, 2027 (estimated) · full calendar
Q3 2026 Nov 14, 2026

Milestone shares fell 20.6% after earnings, as investors likely focused on the gap between launch growth and the company’s need to cut costs: CARDAMYST prescriptions rose 50% quarter over quarter, but Milestone is reducing operating expenses by about 30% and restructuring its commercial organization. The transcript does not provide a revised sales outlook; the cost measures and leadership departures suggest the launch has yet to support the prior operating structure.

Key takeaways
  • CARDAMYST generated approximately 1,800 prescriptions in Q3, up 50% from Q2; cumulative prescriptions since launch reached approximately 3,400.
  • About 750 unique healthcare providers prescribed the drug in Q3, a 16% increase from Q2; cumulative prescribers reached approximately 1,600.
  • Formulary coverage rose to approximately two-thirds of commercially covered lives, from about 50% reported on the prior call.
  • Milestone expects cost measures to reduce operating expenses by approximately 30%, with implementation targeted for completion by Q1 2027; it expects about $2 million in one-time charges.
  • The company said the measures and an extended payment-in-kind interest period are expected to extend cash runway into late 2028, through the anticipated ReVeRA-301 Phase III readout in the second half of 2028.
Q2 2026 Aug 14, 2026

Shares declined 15.7% following the quarter as investors reacted negatively to persistent low market access, with only 25% commercial insurance coverage during Q2 limiting growth potential despite early launch progress.

Key takeaways
  • Total prescriptions grew to over 1,200 in Q2, up from around 300 in Q1, totaling more than 1,500 for the first half of 2026.
  • Unique prescribers increased to over 600 in Q2 from about 200 in Q1, with over 800 total in the first half.
  • Patient count receiving CARDAMYST rose to over 1,000 in Q2 compared to nearly 300 in Q1, totaling more than 1,300 in H1.
  • Commercial formulary coverage remained stagnant at ~25% during Q2, only recently improving to over 50% in July/August, after the reported quarter.
  • Phase III trial for AFib-RVR initiation underway, targeting a larger patient population with symptomatic atrial fibrillation requiring new self-administered treatments.
Q1 2026 May 14, 2026

Shares fell 9.5% following the quarter as investors reacted negatively to cautious early sales performance and a lack of clear near-term revenue acceleration despite a successful product launch and broad coverage progress.

Key takeaways
  • CARDAMYST launched quickly after FDA approval in December 2025 and became available nationwide by end of January 2026.
  • Approximately 600 total prescriptions were recorded through April, with steady month-over-month growth but still limited penetration.
  • Over 400 unique prescribers and about 560 unique patients indicated initial broad physician interest, yet script volume remains modest.
  • Early coverage includes 25% of commercially insured patients, anchored by Express Scripts formulary inclusion.
  • Management highlights positive patient and provider feedback but does not provide explicit revenue or profit guidance, suggesting cautious outlook.